Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.8735 EUR -0.8% Market Closed
Market Cap: 592.5m EUR
Have any thoughts about
Pharming Group NV?
Write Note

Pharming Group NV
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pharming Group NV
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Pharming Group NV
AEX:PHARM
Income from Continuing Operations
-$17.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
1%
ProQR Therapeutics NV
NASDAQ:PRQR
Income from Continuing Operations
-€23.9m
CAGR 3-Years
25%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Income from Continuing Operations
-$239.5m
CAGR 3-Years
N/A
CAGR 5-Years
-18%
CAGR 10-Years
-19%
argenx SE
XBRU:ARGX
Income from Continuing Operations
-$277m
CAGR 3-Years
20%
CAGR 5-Years
-22%
CAGR 10-Years
-51%
Merus NV
NASDAQ:MRUS
Income from Continuing Operations
-$244.6m
CAGR 3-Years
-45%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Income from Continuing Operations
-$42m
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pharming Group NV
Glance View

Market Cap
592.7m EUR
Industry
Biotechnology

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

PHARM Intrinsic Value
1.1978 EUR
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Pharming Group NV's Income from Continuing Operations?
Income from Continuing Operations
-17.8m USD

Based on the financial report for Sep 30, 2024, Pharming Group NV's Income from Continuing Operations amounts to -17.8m USD.

What is Pharming Group NV's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
1%

Over the last year, the Income from Continuing Operations growth was 19%.

Back to Top